

San Francisco

Spring Group Meeting

SPECIALS

Gastrointestinal Committee

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 AYA Committee: Christopher Cann, MD
 Digital Engagement: Heloisa Soares, MD, PhD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals:

CRA: TBD
 Nurse: TBD
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): Carole Seigel, MBA
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, May 2, 2025 4:30 p.m. - 6:30 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

- Welcome
- Announcements & Introductions Philip Philip
E. Gabriela Chiorean
- HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa-Moseley, Carole Seigel, Marielle McLeod
- SWOG Led Trials Updates
 - S1922 Michael Overman
 - S2001 Vincent Chung
 - S2104 Heloisa Soares/Syed Ahmad
 - S2107 Van Morris
 - S2012 David Zhen/E. Gabriela Chiorean
 - S2303 Anwaar Saeed/Paul Oberstein
 - S2408 J. Sham/V. Pillarisetty
 - S2433 Rachael Safyan
- Pancreatic Subcommittee Davendra Sohal, Andrew Lowy
 - Major recent clinical results
 - NCTN trials update
 - Future SWOG plans
- Anal and Rectal Subcommittee Hagen Kennecke, Lisa Kachnic
 - Major recent clinical results
 - NCTN trials update
 - Future SWOG plans

Gastrointestinal Committee

7. Colon Subcommittee Marwan Fakih, Philip Gold, Sepideh Gholami
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
8. Gastroesophageal Subcommittee Syma Iqbal, Zev Wainberg
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
9. Hepatobiliary Subcommittee Anthony El-Khoueiry, Rachna Shroff
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
10. Neuroendocrine Subcommittee Arvind Dasari, Aman Chauhan
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
11. Discussion / Other Business
12. Adjourn

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)", Dr. Saeed, and Dr. Oberstein. Activated: 5/6/24

CTSU/A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.

EA2212, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer" SWOG Champion: Emerson Chen. Temporarily Closed to Accrual as of 12/4/24

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/20.

Closed Studies

CTSU/A021302, Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study. S. Iqbal. Activated by SWOG: 4/1/16.

Pancreatic

Developing Studies

S2433, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma." Drs. R. Safyan, E. Chiorean, H. Singh

Active Studies

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Drs. J. Sham, V. Pillarisetty, R. Krouse. Activated: 2/14/25

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/ Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." SWOG Champion: G. Botta

CTSU/A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Dr. C. Lopez. Activated: 11/2/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

Closed Studies

EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel

Gastrointestinal Committee

Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT).” Activated: 6/18/20. Dr. Zhen. Closed to Accrual as of 10/17/23

CTSU/RTOG-0848, “Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study.” P. Philip. Closed to accrual as of 1/18/19

CTSU/A021501, “Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas.” S. Ahmad. Closed to accrual as of 5/6/19

EA2161, “A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET).” Closed to Accrual & Treatment: 12/27/19

Neuroendocrine

Active Studies

S2104, “Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors.” Dr. Soares. Activated: 10/14/21

S2012, “Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)” Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/2/21

Closed Studies

CTSU/A021602, “Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET).” Dr. Strosberg. Activated: 7/18/18. Closed to Accrual as of 9/8/23

EA2142, “Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas.” SWOG Champion: H. Soares. Closed to Accrual & Treatment: 4/1/21

Hepatobiliary

Active Studies

CTSU/NRG-GI003, “A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma.” Dr. El-Khoueiry. Activated: 6/21/17.

CTSU/EA2197, “Optimal Perioperative Therapy for Incidental Gallbladder

Cancer (OPT-IN): A Randomized Phase II/III Trial.” Dr. Rocha. Activated: 12/22/20.

Closed Studies

S1815, “A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.” Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

CTSU/EA2187, “A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma.” Dr. Stein. Activated: 1/31/20. Permanently Closed: 3/22/23. CTSU/RTOG-1112, Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma. L. Dawson. SWOG Champion: T. Mitin

Colorectal

Active Studies

S1922, “Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma.” Dr. M. Overman

A022101, “A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)” SWOG Champion: S. Gholami Activated: 1/10/23.

EA2222, “A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial” Activated: 10/19/23. SWOG Champion: Skye C. Mayo, MD, MPH

CTSU/NRG-GI008, “Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US).” SWOG GI Committee Co-Chairs: P. Philip & C. Eng Activated: 3/10/22

CTSU/NRG-GI004/ S1610, “Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer.” Dr. Overman. Activated: 11/7/17.

Closed Studies

S2107, “Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer.” Dr. Morris. Study closed to accrual 10/1/24

Gastrointestinal Committee

S1613, “A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification.” Dr. Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23

S0820, “A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).” Dr. Zell. Activated: 3/1/13. Permanently Closed: 6/30/23

CTSU/A021502, “Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair.” Dr. Lieu. Activated: 9/12/17. Permanently Closed: 1/17/23

CTSU/A021703, “Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS).” Dr. Cohen. Activated: 9/30/19. Permanently Closed: 12/15/22

CTSU/E7208, “A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.” H. Hochster. Accrual target: 147 / Final accrual: 136

NRG-GI005, “Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA).” Dr. A. Scott. Activated: 12/16/19. Accrual target: 1408 / SWOG accrual: 35 / NCTN accrual: 635 SWOG Champion: A. Scott Closed to Accrual as of 2/12/24

Anal

Active Studies

A022104, “The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer” Activated 11/9/22. SWOG Champion: A. Dasari

CTSU/EA2176, “Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients.” Dr. Morris. Activated: 10/15/20.

CTSU/EA2182, “A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma

(DECREASE).” Dr. Murphy. Activated: 11/12/19.

CTSU/EA2201, “A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma.” Dr. Cho. Activated 5/13/21.

Closed Studies

CTSU/N1048, “A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision.” C. Eng. Activated: 4/15/12. Accrual target: 1120 / Final accrual: 1194

InterAACT EA2133, “An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease.” V. Morris. Activated: 2/15/16. Accrual target: 80 / Final accrual: 12

NRG-GI002, “A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer.” Activated: 10/12/16. Accrual target: 348/ SWOG accrual: 12 / Final accrual: 363 SWOG Champion: L. Kachnic

EA2165, “A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer.” NCTN activated: 4/13/18. Accrual target: 344 / SWOG accrual: 38 / Final accrual: 383 SWOG Champion: V. Morris

Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1505 Chemotherapy Dose Density is Prognostic for Overall Survival in Patients with Resectable Pancreas Cancer: A Landmark Analysis of SWOG 1505. Patel S, Colby S, Sohal D, Guthrie K, Kachnic L, Chiorean EG, Lowy A, Rocha F, Hochster H, Philip P, Ahmad S. Cancer Feb 15;131(4):e35759, 2025. <https://pubmed.ncbi.nlm.nih.gov/39932777/>

S1613 Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patient with RAS/BRAF wild-type, HER2-positive, Metastatic Colorectal

Gastrointestinal Committee

Cancer (S1613): A Randomized Phase 2 Trial. Raghav K, Guthrie K, Tan B, Denlinger C, Fakih M, Overman M, Dasari NA, Corum L, Hicks L, Patel M, Esparaz B, Kazmi S, Alluri N, Colby S, Gholami S, Gold P, Chiorean EG, Kopetz ES, Hochster H, Philip PA. Journal of Clinical Oncology Jan 6:JCO2401710. doi: 10.1200/JCO-24-01710. Online ahead of print, 2025. <https://pubmed.ncbi.nlm.nih.gov/39761503/>

S1815 SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414). Shroff R, King G, Colby S, Scott A, Borad M, Matin K, Mahipal A, Kalyan A, Javle M, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean EG, Hochster H, Philip P. Journal of Clinical Oncology J Clin Oncol. Feb 10;43(5):536-544, 2025. <https://pubmed.ncbi.nlm.nih.gov/39671534/>

A021602 Phase 3 Trial of Cabozantinib in Previously Treated Advanced Neuroendocrine Tumors. Chan J, Geyer S, Zemla T, Knopp M, Behr S, Pulsipher S, Lou F, Acoba J, Shergill A, Wolin E, Halfdanarson T, Konda B, Trikalinos N, Shaheen S, Vijayvergia N, Dasari A, Strosberg J, Kohn E, Kulke M, O'Reilly E, Meyerhardt J. New England Journal of Medicine Feb 13;392(7):653-665, 2025. <https://pubmed.ncbi.nlm.nih.gov/39282913/>

C80405 Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Cheng E, Ou F, Gatten C, Ma C, Venook A, Lenz H, O'Reilly E, Campbell P, Kuang C, Caan B, Blanke C, Ng K, Meyerhardt J. J Natl Cancer Inst. Jan 1;117(1):169-179, 2025. <https://pubmed.ncbi.nlm.nih.gov/39212617/>

C80405 Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy. Yazdani A, Lenz H, Pilonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, Hadi R, Samiei E, Venook A, Ratain M, Vincent R, Qu B, Wen Y, Kosorok M, Symmans W, Shen J, Lee M, Kopetz S, Nixon A, Bertagnolli M, Perou C, Innocenti F. Commun Med (Lond) Jan 8;5(1):9, 2025. <https://pubmed.ncbi.nlm.nih.gov/39779996/>

C80702 The association of physical activity with survival in colon cancer versus a matched general population: Data from Cancer and Leukemia Group B 89803 and 80702 (Alliance). Brown J, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Goldberg R, Venook A, Blanke CD, O'Reilly E, Shields A, Meyerhardt J. Cancer Mar 1;131(5):e35727, 2025. <https://pubmed.ncbi.nlm.nih.gov/39989023/>

C80702 Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). Brown J, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V,

Goldberg R, O'Reilly E, Shields A, Meyerhardt J. J Natl Cancer Inst. Dec 1;116(12):2032-2039, 2024. <https://pubmed.ncbi.nlm.nih.gov/39180477/>

EA2186 The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. Dotan E, Catalano P, Lenchik L, Boutin R, Yao X, Marques H, Ioffe D, Zhen D, Li D, Wagner L, Simon M, Wong T, O'Dwyer P. J Geriatr Oncol Apr;14(3):101474, 2023. <https://pubmed.ncbi.nlm.nih.gov/36963200/>

Multiple Studies Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA. JCO Precis Oncol. Mar;9:e2400489, 2025.

<https://pubmed.ncbi.nlm.nih.gov/?term=rajdev+l+2025&sort=date>

Submitted Manuscripts

S2303 S2303: Phase II/III Trial of Paclitaxel + Ramucirumab +/- Nivolumab in Gastric and Esophageal Adenocarcinoma (PARAMUNE). Saeed A, Colby S, Oberstein P, Duda D, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger J, Guthrie K, Rocha F, Senthil M, Safyan R, Wainberg Z, Iqbal S, Chiorean G, Philip PA. Submitted.

S0809 The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG S0809. Horowitz D, Colby S, Gholami S, Guthrie KA, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Chiorean E, Rocha F, Ahmad S, Kachnic L. Submitted/in revision.

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Submitted.

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021602	A021806	A022001	A022102	A022104	CCTGC032
Banner University Medical Center - Tucson	-	-	9	-	-	3	1	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	2	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Compr Cancer Cntr	-	-	-	-	-	-	-	-	-	10	-
Boston Medical Center	-	-	-	-	-	3	1	-	3	5	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	2	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-	-
Cancer Research of Wisc & Northern Mich Consort	-	-	-	-	1	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgm	1	1	1	2	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	1	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	1	3	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research CenterLAPS	-	-	2	-	-	-	2	-	-	8	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	2	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-	-	1	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgm	1	-	-	6	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	2	-	3	2	-	-	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	4	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	1	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	1	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	1	-	-	-	-
Northwestern University LAPS	1	-	-	-	-	-	1	-	-	-	-
Ohio State U Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	-	1	-	1	-	1	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021602	A021806	A022001	A022102	A022104	CCTGC032
Pacific Cancer Research Consortium NCORP	-	2	3	2	-	-	-	-	-	-	1
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	1	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	2	-	-	1	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	13	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	2	-
UC Irvine Health/Chao Family Comprehensive Cancer Cntr	-	2	-	4	-	-	-	-	7	5	2
UPMC Hillman Cancer Center LAPS	-	-	-	-	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	1	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	1	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	3	-	9	-	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	8	-	-
University of Kentucky/Markey Cancer Center	-	-	4	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	4	3	2	-	-	4	4	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	2	-	-	-	-	-	-	-
University of Rochester LAPS	1	-	-	-	-	8	11	-	3	19	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	3	-	-	5	-
University of Texas MD Anderson Cancer Center LAPS	13	-	-	10	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	1	-	-	1	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	1	-	-	-	-	-	8	-
Virginia Mason Medical Center	-	-	-	-	-	2	-	-	-	4	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-	-	3	-	-
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	-	-	-	-	2	1	-	-	-
ALLIANCE	12	5	4	8	5	-	-	-	-	-	-
ECOG-ACRIN	2	12	6	14	-	-	-	-	-	-	-
NRG	3	7	8	10	-	-	-	-	-	-	-
Total	40	60	56	88	13	25	31	2	26	82	3

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	CCTGNE1	EA2174	EA2176	EA2182	EA2186	EA2192	EA2197	EA2222	NRGGI004
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	2	-	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	2	-	4	1	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	3	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Comm Oncology Research Program	-	-	-	-	1	-	-	-	-
Fred Hutchinson Cancer Research CenterLAPS	-	-	-	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	1	2	2	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	-	-	8	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	2	-	1	-	-
Northwestern University LAPS	-	-	1	-	1	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	-	-	-
Oregon Health & Science University	-	-	4	1	-	3	5	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	CCTGNE1	EA2174	EA2176	EA2182	EA2186	EA2192	EA2197	EA2222	NRGGI004
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	1	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	4	1	2	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	1	3	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Res Consortium LAPS	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	1	-	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	-	2	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	1	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	7	-	-	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	3	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	10	-	-	-	-	-	13
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	1	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	4	6	34	14	26	4	8	2	15

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGGI005	NRGGI006	NRGGI008
Banner University Medical Center - Tucson	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	3	-	2
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	1
Boston Medical Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Comm Oncology Research Program	1	-	-
Fred Hutchinson Cancer Research CenterLAPS	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Health Providence Southfield Hospital	5	-	1
Henry Ford Hospital	1	-	-
Houston Methodist Hospital	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	11	-	-
Loma Linda University Medical Center	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	-
Moffitt Cancer Center	-	-	-
Montana Cancer Consortium NCORP	-	-	-
NCORP of the Carolinas	-	-	-
Northwell Health NCORP	1	-	1
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health & Science University	1	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	NRGG1005	NRGG1006	NRGG1008
Pacific Cancer Research Consortium NCORP	-	-	-
STCC at DHR Health Institute for Research & Development	1	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-
The West Clinic - Wolf River	-	-	3
UC Davis Comprehensive Cancer Center LAPS	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-
University of Colorado Cancer Center LAPS	-	-	6
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	1
University of Rochester LAPS	-	-	7
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	3
Virginia Mason Medical Center	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	4	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	35	1	27

